Cutaneous lupus erythematosus: a bibliographic review
Main Article Content
Keywords
Cutaneous Lupus Erythematosus, Systemic Lupus Erythematosus, Discoid Lupus Erythematosus
Abstract
Cutaneous lupus erythematosus embraces a wide variety of dermatological manifestations not necessarily linked to systemic disease. The pathophysiology is not completely understood, however it is believed to be an interaction between molecular, genetic and environmental factors such as ultraviolet light which is an important triggering factor. The sintomatology may be specific for lupus or inespecific. The specific lesions include: acute, subacute, chronic and intermittent lupus erythematosus. These are divided according to clinical manifestations, evolution, histological and laboratory findings. The treatment includes the non-pharmacological and pharmacological therapy, emphasizing patient education regarding photoprotection and administration of topical or systemic treatment.
References
2. Grönhagen C, Nyberg F. Cutaneous lupus erythematosus: An update. Indian Dermatol Online J. 2014;5(1):7.
3. Kuhn A, Landmann A. The classification and diagnosis of cutaneous lupus erythematosus. J Autoimmun. 2014;49:14–19. doi: 10.1016/j.jaut.2014.01.021
4. Kalus A. Rheumatologic Skin Disease. Med Clin North Am. 2015;99(6):1287–1303.
5. Wenzel J. Cutaneous lupus erythematosus: new insights into pathogenesis and therapeutic strategies. Nat Rev Rheumatol. 2019;15(9):519–532.
6. Kuhn A, Wenzel J, Bijl M. Lupus erythematosus revisited. Semin Immunopathol. 2016;38(1):97–112.
7. Chang J, Werth VP. Therapeutic options for cutaneous lupus erythematosus: recent advances and future prospects. Expert Rev Clin Immunol. 2016;12(10):1109–1121.
8. Wieczorek IT, Propert KJ, Okawa J, Werth VP. Systemic symptoms in the progression of cutaneous to systemic lupus erythematosus. JAMA Dermatology. 2014;150(3):291–296.
9. Merola JF. Overview of cutaneous lupus erythematosus. UpToDate. 2019;1: 1–59.
10. Achtman JC, Werth VP. Pathophysiology of cutaneous lupus erythematosus. Clin Rev Allergy Immunol. 2007;33(1–2):85–106.
11. Stannard JN, Kahlenberg JM. Cutaneous lupus erythematosus: Updates on pathogenesis and associations with systemic lupus. Curr Opin Rheumatol. 2016;28(5):453–459.
12. Hejazi EZ, Werth VP. Cutaneous Lupus Erythematosus: An Update on Pathogenesis, Diagnosis and Treatment. Am J Clin Dermatol. 2016;17(2):135–146.
13. Prettel M, Marquès L, España A. Lupus eritematoso inducido por fármacos. Actas Dermosifiliogr. 2014;105(1):18–30.
14. Fiorentino DF. The yin and yang of eIF3. Nat Struct Mol Biol . 2015;22(5):361. doi: 10.1038/nsmb.3026
15. Uva L, Miguel D, Pinheiro C, et al. Cutaneous manifestations of systemic lupus erythematosus. Autoimmune Dis. 2012;1(1).
16. Jarrett P, Werth VP. A review of cutaneous lupus erythematosus: improving outcomes with a multidisciplinary approach. J Multidiscip Healthc. 2019; 12:419–428.
17. Kuhn A, Aberer E, Bata-Csörgő Z et al. S2k guideline for treatment of cutaneous lupus erythematosus – guided by the European Dermatology Forum (EDF) in cooperation with the European Academy of Dermatology and Venereology (EADV). J Eur Acad Dermatology Venereol. 2017;31(3):389–404.
Article Sidebar
Article Details
Copyright (c) 2020 Universidad Hispanoamericana
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
RHCS uses the Creative Commons License 4.0 International (CC BY 4.0). For more information, please visit